Announcement • Jun 20
Volato Group, Inc. announced that it has received $2.21 million in funding from Catheter Precision, Inc. On June 18, 2026, Volato Group, Inc. has closed the transaction. Announcement • Jun 09
Volato Group, Inc. announced that it expects to receive $1 million in funding from Catheter Precision, Inc. Volato Group, Inc. entered into a securities purchase agreement with new investor Catheter Precision, Inc. for issuance of 2,941,176 common shares at a price of $0.34 per share for gross proceeds of $999,999.84 on June 7, 2026. Subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below), and/or Rule 506 of Regulation D promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. Announcement • Jun 05
Volato Group, Inc. Announces NYSE American Acceptance of Compliance Plan As previously disclosed, on March 17, 2026, Volato Group, Inc., a Delaware corporation (the Company), received a notice from the NYSE American LLC (the NYSE American) advising the Company that it is not in compliance with the NYSE American continued listing standards set in Section 1003(a)(i) and Section 1003(a)(ii) of the NYSE American Company Guide. The Company was required to submit a plan to the NYSE American by April 16, 2026 outlining actions it has taken or will take to regain compliance with the continued listing standards by December 17, 2026 (the Plan). The Company submitted the Plan to the NYSE American on April 16, 2026. On June 3, 2026, the Company received a notice from the NYSE American advising the Company that the NYSE American reviewed and accepted the Company's Plan and that the Company has until December 17, 2026 to regain compliance with the applicable continued listing standards. There is no immediate impact on the listing of the Company's shares of common stock on the NYSE American. The Company's common stock will continue to be listed and traded on the NYSE American under the ticker SOAR during the period allotted for the Company to regain compliance, subject to the Company's compliance with the other continued listing standards of the NYSE American. The Company is committed to regaining compliance with the NYSE American's continued listing standards. However, there can be no assurance that the Company will ultimately regain compliance with all applicable continued listing standards within the allotted compliance period or that developments and events occurring subsequent to the Company's formulation of the plan will not adversely affect the Company's ability to make sufficient progress with the plan, regain compliance with all applicable continued listing standards, or maintain compliance with other NYSE American continued listing standards. If the Company does not regain compliance by December 17, 2026, or does not make progress consistent with its plan during the plan period, the NYSE American may initiate delisting proceedings. 
